Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BF30 Single-dose Therapy in Peripheral Arterial Occlusive Disease
NCT03668353Phase 1Unknown
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of DVC1-0101 in peripheral arterial occlusive disease (PAOD) and critical limb ischemia (CLI) (4 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Status: unknown.
02
Drugs
DVC1-0101
03
Conditions
peripheral arterial occlusive disease (PAOD)critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03668353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668353.